Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
12 Jul 2021
12 Jul 2021
Historique:
entrez:
16
7
2021
pubmed:
17
7
2021
medline:
17
7
2021
Statut:
epublish
Résumé
Following the discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its rapid spread throughout the world, new viral variants of concern (VOC) have emerged. There is a critical need to understand the impact of the emerging variants on host response and disease dynamics to facilitate the development of vaccines and therapeutics. Syrian golden hamsters are the leading small animal model that recapitulates key aspects of severe coronavirus disease 2019 (COVID-19). In this study, we show that intranasal inoculation of SARS-CoV-2 into hamsters with the ancestral virus (nCoV-WA1-2020) or VOC first identified in the United Kingdom (B.1.1.7) and South Africa (B.1.351) led to similar gross and histopathologic pulmonary lesions. Although differences in viral genomic copy numbers were noted in the lungs and oral swabs of challenged animals, infectious titers in the lungs were comparable. Antibody neutralization capacities varied, dependent on the original challenge virus and cross-variant protective capacity. Transcriptional profiling indicated significant induction of antiviral pathways in response to all three challenges with a more robust inflammatory signature in response to B.1.1.7. Furthermore, no additional mutations in the spike protein were detected at peak disease. In conclusion, the emerging VOC showed distinct humoral responses and transcriptional profiles in the hamster model compared to the ancestral virus.
Identifiants
pubmed: 34268506
doi: 10.1101/2021.07.11.451964
pmc: PMC8282094
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI152258
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001414
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
J Virol. 2011 Oct;85(19):9929-44
pubmed: 21775442
Emerg Microbes Infect. 2020 Dec;9(1):2673-2684
pubmed: 33251966
Science. 2020 Aug 7;369(6504):712-717
pubmed: 32527928
J Virol. 2013 Apr;87(8):4778-82
pubmed: 23388711
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Sci Rep. 2020 Nov 10;10(1):19395
pubmed: 33173052
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28336-28343
pubmed: 33082228
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Annu Rev Virol. 2015 Nov;2(1):265-88
pubmed: 26958916
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Lancet. 2020 Aug 1;396(10247):320-332
pubmed: 32682491
Nat Commun. 2014 May 21;5:3864
pubmed: 24844667
Immunology. 2013 Oct;140(2):168-78
pubmed: 23600567
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
Cell. 2021 Jun 24;184(13):3426-3437.e8
pubmed: 33991487
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Immunol Methods. 2011 May 31;368(1-2):24-35
pubmed: 21334343
J Gen Virol. 2008 Jan;89(Pt 1):1-47
pubmed: 18089727
J Infect Dis. 2013 Jan 15;207(2):306-18
pubmed: 23045629
Emerg Infect Dis. 2020 Sep;26(9):2005-2015
pubmed: 32437316
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Sci Transl Med. 2021 Jan 27;13(578):
pubmed: 33431511
Am J Trop Med Hyg. 2021 Apr 20;:
pubmed: 33878029
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Cell Stem Cell. 2020 Dec 3;27(6):962-973.e7
pubmed: 32979316
Virology. 2015 Nov;485:305-12
pubmed: 26319212
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
N Engl J Med. 2021 Mar 8;384(15):1466-1468
pubmed: 33684280
Front Immunol. 2020 Aug 26;11:2037
pubmed: 32983152
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Genome Biol. 2017 Jan 19;18(1):4
pubmed: 28100256
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
BMC Bioinformatics. 2016 Sep 20;17:388
pubmed: 27650223
Virus Res. 2020 Dec;290:198197
pubmed: 33069815
Lancet. 2021 Feb 6;397(10273):452-455
pubmed: 33515491
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Emerg Infect Dis. 2020 Jun;26(6):1266-1273
pubmed: 32160149
Cell Rep. 2020 Oct 6;33(1):108234
pubmed: 32979938
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
J Virol. 2009 Jul;83(14):7285-95
pubmed: 19403663
Cell. 2020 Jun 25;181(7):1475-1488.e12
pubmed: 32479746
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413740
Inflammopharmacology. 2021 Feb;29(1):91-100
pubmed: 33159646
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
PLoS Negl Trop Dis. 2013;7(1):e2024
pubmed: 23342177
FEBS Lett. 2021 May;595(10):1454-1461
pubmed: 33728680
Lancet Microbe. 2020 Nov;1(7):e290-e299
pubmed: 33015653
EBioMedicine. 2021 Jun;68:103403
pubmed: 34049240
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Science. 2021 Jun 24;:
pubmed: 34168070
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
J Virol. 2007 Jan;81(1):20-9
pubmed: 16928755
PLoS One. 2014 Nov 14;9(11):e112617
pubmed: 25398096
Nat Commun. 2020 Jul 30;11(1):3810
pubmed: 32733001
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Radiology. 2020 Apr;295(1):210-217
pubmed: 32027573
Mol Cell Proteomics. 2015 Mar;14(3):646-57
pubmed: 25573744
Genes Immun. 2005 Jun;6(4):319-31
pubmed: 15789058